Original Research
Accepted on 18 Nov 2024
Neuroblastoma response to RAS-MAPK inhibitors and APR-246 (eprenetapopt) co-treatment is dependent on SLC7A11
in Cancer Molecular Targets and Therapeutics
Original Research
Accepted on 18 Nov 2024
in Cancer Molecular Targets and Therapeutics
Original Research
Accepted on 18 Nov 2024
in Gastrointestinal Cancers: Colorectal Cancer
Original Research
Accepted on 18 Nov 2024
in Thoracic Oncology
Original Research
Accepted on 18 Nov 2024
in Surgical Oncology
Review
Accepted on 18 Nov 2024
in Surgical Oncology
Original Research
Accepted on 18 Nov 2024
in Radiation Oncology
Case Report
Accepted on 18 Nov 2024
in Gastrointestinal Cancers: Colorectal Cancer
Original Research
Accepted on 18 Nov 2024
in Thoracic Oncology
Editorial
Accepted on 18 Nov 2024
in Pharmacology of Anti-Cancer Drugs
Case Report
Accepted on 18 Nov 2024
in Gastrointestinal Cancers: Gastric and Esophageal Cancers
Editorial
Accepted on 18 Nov 2024
in Pharmacology of Anti-Cancer Drugs
Original Research
Accepted on 18 Nov 2024
in Gastrointestinal Cancers: Gastric and Esophageal Cancers
Correction
Accepted on 18 Nov 2024
in Pharmacology of Anti-Cancer Drugs
Case Report
Accepted on 18 Nov 2024
in Neuro-Oncology and Neurosurgical Oncology
Original Research
Accepted on 18 Nov 2024
in Breast Cancer
Editorial
Accepted on 18 Nov 2024
in Breast Cancer